Medication info
Nutrasset Tablet

Nutrasset Tablet

Prescription medicationTabletOral
Ingredient · strength
Acetaminophen›325mg / 1 tabletTramadol Hydrochloride›37.5mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
Pale yellow oblong film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200709909 · Notified 2007.08.28 · Insurance code 665000220

Summary

Main use
Relief of moderate to severe acute and chronic pain
Who takes it
Adults · Children
Adult dose
Adults: The dose should be adjusted according to the patient's pain severity and response to treatment. An initial dose of 2 tablets is recommended. Thereafter, doses should be given at intervals of at least 6 hours, and no more than 8 tablets should be taken in 1 day. Administer the lowest effective dose for the shortest possible duration. Do not administer this medicine for longer than necessary. If long-term administration is required due to the nature and severity of the condition, perform regular monitoring to determine whether treatment with this medicine should be continued. Elderly patients Administer the usual adult dose. However, since the elimination half-life of tramadol increased by 17% when tramadol was given orally to elderly patients aged 75 years or older, administer this medicine at intervals of at least 6 hours. Patients with renal impairment For patients with moderate renal impairment (creatinine clearance of 10-30ml/min), extend the dosing interval to 12 hours. Administration is not recommended for patients with severe renal impairment (creatinine clearance below 10ml/min). Since tramadol is removed very slowly by hemodialysis and filtration, there is no need to readminister this medicine after dialysis to maintain the analgesic effect. Patients with hepatic impairment Carefully consider extending the dosing interval for patients with moderate hepatic impairment. Do not administer this medicine to patients with severe hepatic impairment.
Child dose
Children aged 12 years and older: The dose should be adjusted according to the patient's pain severity and response to treatment. An initial dose of 2 tablets is recommended. Thereafter, doses should be given at intervals of at least 6 hours, and no more than 8 tablets should be taken in 1 day. Administer the lowest effective dose for the shortest possible duration. Do not administer this medicine for longer than necessary. If long-term administration is required due to the nature and severity of the condition, perform regular monitoring to determine whether treatment with this medicine should be continued.

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Relief of moderate to severe acute and chronic pain

  • Moderate to severe acute and chronic pain.
View approved original text

This medication is used to relieve acute and chronic pain ranging from moderate to severe.

How to take

Adult dose

Adults: The dose should be adjusted according to the patient's pain severity and response to treatment. An initial dose of 2 tablets is recommended. Thereafter, doses should be given at intervals of at least 6 hours, and no more than 8 tablets should be taken in 1 day. Administer the lowest effective dose for the shortest possible duration. Do not administer this medicine for longer than necessary. If long-term administration is required due to the nature and severity of the condition, perform regular monitoring to determine whether treatment with this medicine should be continued. Elderly patients Administer the usual adult dose. However, since the elimination half-life of tramadol increased by 17% when tramadol was given orally to elderly patients aged 75 years or older, administer this medicine at intervals of at least 6 hours. Patients with renal impairment For patients with moderate renal impairment (creatinine clearance of 10-30ml/min), extend the dosing interval to 12 hours. Administration is not recommended for patients with severe renal impairment (creatinine clearance below 10ml/min). Since tramadol is removed very slowly by hemodialysis and filtration, there is no need to readminister this medicine after dialysis to maintain the analgesic effect. Patients with hepatic impairment Carefully consider extending the dosing interval for patients with moderate hepatic impairment. Do not administer this medicine to patients with severe hepatic impairment.

Child dose

Children aged 12 years and older: The dose should be adjusted according to the patient's pain severity and response to treatment. An initial dose of 2 tablets is recommended. Thereafter, doses should be given at intervals of at least 6 hours, and no more than 8 tablets should be taken in 1 day. Administer the lowest effective dose for the shortest possible duration. Do not administer this medicine for longer than necessary. If long-term administration is required due to the nature and severity of the condition, perform regular monitoring to determine whether treatment with this medicine should be continued.

Precautions

This medication may put a strain on the liver; therefore, those who regularly consume more than three glasses of alcohol a day should consult with a doctor or pharmacist before taking it. This medication can rarely cause serious skin allergic reactions; if a rash or hypersensitivity occurs, discontinue use immediately. The ingredients in this medication can increase the risk of seizures; caution is required if you have a history of seizures or are taking medications that increase seizure risk. Patients with impaired respiratory function or severe bronchial asthma may experience life-threatening respiratory depression when taking this medication; it should be taken in an environment where medical personnel can monitor the patient. Taking this medication in conjunction with alcohol or central nervous system depressants can lead to severe sedation, respiratory depression, coma, and even death; it is advisable to avoid combination or use the minimum dosage for a short period if necessary. Patients with elevated intracranial pressure or head injuries may be at risk of increased brain pressure when taking this medication; caution is needed. This medication can lead to physical and psychological dependence; therefore, prolonged use should be closely monitored for signs of dependency. Patients with compromised liver function should consult a doctor before taking this medication, as its components may stress the liver. Patients with certain genetic traits (CYP2D6 ultra-rapid metabolizers) may have elevated concentrations of the active metabolite, increasing the risk of severe respiratory depression; dosage adjustment and close monitoring are necessary. This medication should not be given to children under 12 years old and adolescents under 18 years old who have undergone tonsillectomy or adenoidectomy. Adolescents aged 12 to 18 should avoid use if they have specific risk factors. This medication can exacerbate sleep apnea and hypoxemia; if symptoms change, consideration should be given to adjusting or discontinuing the dosage. Elderly patients or those at risk of hyponatremia should be closely monitored for the occurrence of hyponatremia during treatment with this medication. This medication should not be given to patients allergic to certain components, those with central nervous system drug dependence, those with severe respiratory depression, those with head injuries, those on MAO inhibitors, those with severe liver, kidney, or heart dysfunction, nursing mothers, children under 12 years old, adolescents under 18 years old after specific surgeries, and patients with aspirin-induced asthma. This medication increases the risk of seizures and respiratory depression when combined with other central nervous system depressants, opioids, or antidepressants; caution is warranted, and minimal doses should be used for the shortest duration necessary. Drowsiness or dizziness may occur during use, so caution should be exercised when driving or operating machinery. In case of overdose, serious respiratory depression, seizures, liver damage, and other severe complications may occur, so do not exceed the recommended dosage, and seek medical attention immediately if overdose is suspected. This medication should be kept out of the reach of children, and access to it should be restricted to prevent misuse or abuse.

Side effects

Liver damage, acute generalized exanthematous pustulosis, Stevens-Johnson syndrome, toxic epidermal necrolysis, seizures, anaphylactic reactions, respiratory depression, deep sedation, coma, hepatotoxicity, hyponatremia, loss of appetite, insomnia, depression, dizziness, headache, drowsiness, nausea, vomiting, constipation, dry mouth, diarrhea, indigestion, abdominal pain, abdominal discomfort, flatulence, pruritus, sweating, rash, fatigue, flushing, urticaria, hypersensitivity, hypoglycemia, anxiety, irritability, emotional instability, euphoria, decreased libido, sleep disturbances, confusion, disorientation, agitation, abnormal dreams, substance abuse, hallucinations, withdrawal syndrome, migraine, somnolence, sensory loss, tremors, paresthesia, attention deficit, syncope, memory impairment, psychomotor activation, sedation, amnesia, perceptual disturbances, convulsions, blurred vision, visual impairment, miosis, dizziness, tinnitus, ear discomfort, palpitations, tachycardia, hypertension, hypotension, dyspnea, dry throat, increased liver enzymes, generalized pruritus, diaphoresis, urinary disturbance, erectile dysfunction, weakness, chest pain, abnormal emotions, chills, chest discomfort, lethargy, drug withdrawal syndrome, thirst, irritability, hot flashes, weight loss, increased serum creatinine, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, emotional instability, delirium, suicidal thoughts, muscular hypertonia, movement disorders, serotonin syndrome, speech disorders, mydriasis, orthostatic hypotension, hepatitis, gait disturbance, prolonged prothrombin time, thrombocytopenia, agranulocytosis, blood disorders, hypoprothrombinemia, high anion gap metabolic acidosis, fixed exanthema, weakness, fever, edema, rigidity, syncope, congestive heart failure, vertigo, confusion, exacerbation of migraine, involuntary muscle contractions, dyspnea, asthma, exercise-induced dyspnea, cough, bronchitis, urine retention, increased frequency of urination, abnormalities in kidney function tests, oliguria, rash, increased sweating, urticaria, dysphagia, tongue swelling, increased salivation, progression of colorectal cancer, progression of esophageal cancer, progression of gastric cancer, paralytic ileus, hiccups, cholecystitis, drowsiness, insomnia, irritability, hallucinations, depersonalization, anemia, decreased hemoglobin, decreased red blood cells, decreased white blood cells, increased white blood cells, decreased platelets, arrhythmia, exacerbation of hypertension, aortic stenosis, gastrointestinal bleeding, increased cholesterol, tinnitus, chills, pain in the hip, thigh pain, allergic rhinitis, nasal bleeding, abnormal vision, progression of bile duct cancer, foreign body sensation in the eye, progression of liver cancer, liver function abnormalities, nausea, dizziness, paralytic ileus, cholecystitis, abnormalities in kidney function tests, increased salivation, gastrointestinal bleeding, nausea, dizziness, dyspnea, confusion, migraine, speech disorders, loss of consciousness, recurrence of myocardial infarction, hypotension, vomiting, indigestion, confusion, multiple organ failure, anaphylaxis, intentional overdose, belching, chest discomfort, anxiety, sweating, rigidity, pain, diarrhea, upper respiratory syndrome, tongue biting, agitation, hyperactivity, panic attacks, severe anxiety, hallucinations, perceptual disturbances, tinnitus, abnormal central nervous system reactions, anaphylactic reactions, urticaria, bronchospasm, toxic skin necrosis, myocardial infarction, QT prolongation, respiratory depression, somnolence, coma, death, liver failure, renal tubular necrosis, coagulopathy, abdominal discomfort, lethargy, pallor, increased sweating, acute or chronic adrenal insufficiency, severe abdominal pain, hypotension, extreme fatigue, loss of appetite, weight loss, opioid-induced hyperalgesia, withdrawal symptoms, respiratory arrest

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. Additionally, it is recommended to store it at room temperature between 1°C and 30°C. This helps to maintain the effectiveness of the drug.

Appearance and packaging

Appearance

Pale yellow oblong film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.